[Acute leukemia successfully treated with natural interferon-alpha]

Area of Science:

• Oncology
• Immunology
• Hematology

Background:

• Acute leukemia presents with increased blast cells and often requires intensive chemotherapy.
• Conventional chemotherapy regimens like BHAC-DMP and low-dose Ara-C can be ineffective in certain leukemia cases.
• Interferon-alpha (IFN-alpha) is a cytokine with known immunomodulatory and antiproliferative effects.

Observation:

• A 42-year-old male patient with acute leukemia presented with hypocellular bone marrow and 50% blast infiltration.
• The patient's leukemia was refractory to initial treatment with BHAC-DMP and low-dose Ara-C chemotherapy.
• Natural interferon-alpha (nIFN-alpha) was administered as a monotherapy.

Findings:

• Treatment with nIFN-alpha resulted in a significant reduction of bone marrow blasts to below 3% within one month.
• Peripheral blood cell counts normalized following nIFN-alpha therapy.
• The patient achieved and maintained a complete remission for at least seven months.

Implications:

• Natural interferon-alpha may represent a viable therapeutic option for acute leukemia refractory to standard chemotherapy.
• IFN-alpha monotherapy demonstrates potential in inducing and sustaining long-term remission in leukemia patients.
• Further investigation into interferon-based therapies for hematological malignancies is warranted.